Friday, September 19, 2014

Participate in Research

Human Subjects Protection Training
Participate in Research 
Researchers
Research Studies 


We are currently seeking participants for the following studies:

HPV Prevalence Study

The HPV Prevalence Study is currently recruiting biologically born males (regardless of gender expression or identity) aged 18-26 to help us determine the prevalence of human papillomavirus (HPV) and assess knowledge, attitudes, and practices regarding HPV vaccination. Participants will be compensated for their time.

If interested, please contact Michael Maloney at 773.388.8898 or MMaloney@howardbrown.org. 


btqlogo2013.jpg

Bitch to Quit (BTQ) Smoking Cessation Research Study 

The Bitch to Quit program was specifically developed to address the needs of LGBTQ smokers. The program is based on knowledge and activities that have been proven to be effective with heterosexual smokers. In addition, we have created new materials that are LGBTQ specific. The Bitch to Quit program includes group counseling sessions with trained facilitators, nicotine replacement, and peer support. Our first goal of this project is to help YOU reach your stop smoking goals. Our second goal is to test how well the program works for LGBTQ smokers in general.

BTQ exists because smoking rates in the LGBTQ communities are sky high. Results of a recent study show that approximately 35% of all LGBTQ people smoke – this compares to about 20% of all heterosexual people. Despite higher smoking rates, there are very few stop smoking programs that have been specifically developed for LGBTQ smokers. Many experts agree that we need to develop and test programs that can assist LGBTQ smokers who are ready to quit. Bitch to Quit (BTQ) is proud to be one of the first studies in the nation focusing on smoking in the LGBTQ community! The study is currently seeking adult lesbian, gay, bisexual, transgender, and queer (LGBTQ) smokers who are interested in quitting smoking. The study includes 6 group-counseling sessions, 8 weeks of nicotine patches, and compensation for time and travel!

For more information, please call 773-388-8868 or e-mail
 BTQ@howardbrown.org


Currently Recruiting Clinical Trials

Gilead GS-US-292-0117
Gilead GS-US-292-0117 is an Phase 3, Two-Part Study to Evaluate the Efficacy of Tenofovir Alafenmide versus Placebo Added to a Failing Regimen Followed by Treatment with Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1 Positive, Antiretroviral Treatment-Experienced Adults. Eligible participants receive study medication and associated labs at no charge and are compensated for time. The Principal Investigator (PI) for this study is Dr. Catherine Creticos, MD.

For more information, please contact Kenyetta Drummond at
 KenyettaD@howardbrown.org or 773-572-5116. 

Gilead GS-US-292-0119
Gilead GS-US-292-0119 in an Phase 3 Open-Label Study to Evaluate Switching from Optimized Stable Antiretroviral Regimens Containing Darunavir to Elvitegravir/Cobicistat/Emtricitabine/Tenefovir Alafenamide (E/C/F/TAF) Single Tablet Regimen (STR) plus Darunavir (DRV) in Treatment Experienced HIV-1 Positive Adults. Eligible participants receive study medication and associated labs at no charge and are compensated for time. The Principal Investigator (PI) for this study is Dr. Catherine Creticos, MD.

For more information, please contact Kenyetta Drummond at KenyettaD@howardbrown.org or 773-572-5116.